Cyclosporine a (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)

Journal of Neural Transmission

Volumn 113, Issue 7, 2006, Pages 787-801

  Schmitt, U ^a   Abou El Ela, A ^a   Guo, L J ^a,e   Glavinas, H ^b   Krajcsi, P ^b   Baron, J M ^c   Tillmann, C ^d   Hiemke, C ^a   Langguth, P ^a   Hartter S ^a,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Amisulpride; Antipsychotics; Behavior; CsA; Drug drug interaction; P gp

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMISULPRIDE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBON 14; CYCLOSPORIN A; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOPROTEIN P; MANNITOL; RADIOLIGAND; TALINOLOL; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BIOTRANSFORMATION; CELL STRAIN CACO 2; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BLOOD-BRAIN BARRIER; BRAIN; CACO-2 CELLS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES; MOTOR ACTIVITY; P-GLYCOPROTEIN; RADIOLIGAND ASSAY; RATS; SULPIRIDE; TIME FACTORS;

EID: 33745491975     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0367-4     Document Type: Article

References (49)

1. A Abou el Ela S Härtter U Schmitt C Hiemke H Spahn-Langguth P Langguth 2004 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates J Pharm Pharmacol 56 967 975
2. S Ayesh YM Shao WD Stein 1996 Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein Biochim Biophys Acta 1316 8 18
3. JM Baron LB Goh Y Denggao CR Wolf T Friedberg 2001a Modulation of P450 CYP3A4 dependent metabolism by P-glycoprotein: Implication for P450 phenotyping J Pharmacol Exp Ther 296 351 358
4. JM Baron D Höller R Schiffer S Frankenberg M Neis HF Merk FK Jugert 2001b Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes J Invest Dermatol 116 541 548
5. CV Borlongan CE Stahl T Fujisaki PR Sanberg S Watanabe 1999 Cyclosporine A-induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Cell Transplant 8 153 159
6. P Borst AH Schinkel 1998 P-glycoprotein, a guardian of the brain WM Pardridge Introduction to the blood-brain barrier Cambridge University Press Cambridge 198 206
7. AJ Coukell CM Spencer P Benfield 1996 Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia CNS Drugs 6 237 256
8. KMM Doan JE Humphreys LO Webster SA Wring LJ Shampine CJ Serabjit KK Adkison JW Polli 2002 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J Pharmacol Exp Ther 303 1029 1037
9. 3H] verapamil radioligand-binding assay J Pharmacol Exp Ther 288 348 357
10. P Doze A van Waarde PH Elsingha NH Hendrikse W Vaalburg 2000 Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier Synapse 36 66 74
11. J Drewe HA Ball C Beglinger B Peng A Kemmler H Schächinger WE Haefeli 2000 Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine Br J Clin Pharmacol 50 237 246
12. AI Esquifino A Arce MA Vicente-Torres PE Gil-Loyzaga 1998 Effects of acute and chronic administration of cyclosporine on dopamine metabolism in the rat cochlea J Physiol Biochem 54 149 154
13. MM Gottesman I Pastan 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem 62 385 427
14. S Härtter S Hüwel T Lohmann A Abou el Ela P Langguth C Hiemke H-J Galla 2003 How does the benzamide antipsychotic amisulpride get into the brain? - An in vitro approach comparing amisulpride with clozapine Neuropsychopharmacol 28 1916 1922
15. Hanafy A (2001) Transport inhibition and induction as sources for absorption and disposition related drug drug interactions: Talinolol as model substrate for the ABC transporter P-glycoprotein. Thesis, University Halle/Saale, Germany
16. L Jetté GF Murphy R Béliveau 1998 Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment Int J Cancer 76 729 737
17. M King W Su A Chang A Zuckerman GW Pasternak 2001 Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs Nat Neurosci 4 268 274
18. C Lau F Ma Y Wang C Smith 1996 Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics Psychopharmacol 126 241 248
19. SP Letrent GM Pollack KR Brouwer KLR Brouwer 1999 Effect of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat Drug Metab Dispos 27 827 834
20. DR Luke LJ Brunner K Vadiei 1990 Bioavailability assessment of cyclosporine in the rat. Influence of route of administration Drug Metab Dispos 18 158 162
21. JR Murren HJ Durivage AC Buzaid M Reiss SD Flynn D Carter WN Hait 1996 Trifluperazine as a modulator of multidrug resistance in refractory breast cancer Cancer Chemother Pharmacol 38 65 70
22. Nonmem Project Group (1998) Nonmem user guide. Beal SL, Sheiner LB (eds) University of California, San Francisco
23. I Pajeva M Wiese 1998 Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study J Med Chem 41 1815 1826
24. L Pani GL Gessa 2002 The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia Mol Psychiatry 7 247 253
25. WM Pardridge 1998 Blood-brain barrier methodology and biology WM Pardridge Introduction to the blood-brain barrier Cambridge University Press Cambridge 1 8
26. WM Pardridge 2002 Drug and gene delivery to the brain: the vasular route Neuron 36 555 558
27. 3 dopamine receptor antagonist activity and limbic selectivity J Pharmacol Exp Ther 280 73 82
28. JW Polli SA Wring JE Humphreys L Huang JB Morgan LO Webster CS Serabjit-Singh 2001 Rational use of in vitro P-glycoprotein assays in drug discovery J Pharmacol Exp Ther 299 620 628
29. VV Rao JL Dahlheimer ME Bardgett AZ Snyder RA Finch AC Sartorelli D Piwnica-Worms 1999 Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier Proc Natl Acad Sci USA 96 3900 3905
30. LL Rubin JM Staddon 1999 The cell biology of the blood-brain barrier Annu Rev Neurosci 22 11 28
31. PA Russel DI Williams 1973 Effects of repeated testing on rats' locomotor activity in the open-field Anim Behav 21 109 111
32. J Sachse S Härtter H Weigmann C Hiemke 2003 Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection J Chromatogr B 784 405 410
33. A Sakata I Tamai K Kawazu Y Deguchi T Ohnishi A Saheki AS Tsuji 1994 In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier Biochem Pharmacol 48 1989 1992
34. B Sarkadi EM Price RC Boucher UA Germann GA Scarborough 1992 Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase J Biol Chem 267 4854 4858
35. B Sarkadi I Szasz A Gerloczi G Gardos 1977 Transport parameters and stoichiometry of active calcium ion extrusion in intact human red cells Biochim Biophys Acta 464 93 107
36. S Scala N Akhmed US Rao K Paull LB Lan B Dickstein JS Lee GH Elgemeie WD Stein SE Bates 1997 P-glycoprotein substrates and antagonists cluster into two distinct groups Mol Pharmacol 51 1024 1033
37. B Scatton Y Claustre A Cudennec A Oblin G Perrault DJ Sanger H Schoemaker 1997 Amisulpride: from animal pharmacology to therapeutic action Int Clin Psychopharmacol 12 Suppl 2 S29 S36
38. AH Schinkel E Wagenaar CAAM Mol L van Deemter 1996 P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 2517 2524
39. H Schoemaker Y Claustre D Fage L Rouquier K Chergui O Curet A Oblin F Gonon C Carter J Benavides B Scatton 1997 Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity J Pharmacol Exp Ther 280 83 97
40. S Seetheraman MA Barrand L Maskell RJ Scheper 1998 Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates J Neurochem 70 1151 1159
41. LE Shapiro NH Shear 2002 Drug interactions: proteins, pumps, and P450s J Am Acad Dermatol 47 467 484
42. Y Shitara T Itoh H Sato AP Li Y Sugiyama 2003 Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A J Pharmacol Exp Ther 304 610 616
43. H Spahn-Langguth G Baktir A Radschuweit A Okyar B Terhaag P Ader A Hanafi P Langguth 1998 P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound Int J Clin Pharmacol Ther 36 16 24
44. PA Stewart R Béliveau KA Rogers 1996 Cellular localization of P-glycoprotein in brain versus gonadal capillaries J Histochem Cytochem 44 679 685
45. T Terasaki K Hosoya 1999 The blood-brain barrier efflux transporters as a detoxifying system for the brain Adv Drug Delivery Rev 36 195 209
46. F Thiebaut T Tsuruo H Hamada MM Gottesmann I Pastan MC Willingham 1987 Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissue Proc Natl Acad Sci USA 84 7735 7738
47. F Tiberghien F Loor 1996 Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay Anti-Cancer Drugs 7 568 578
48. A Tsuji I Tamai 1997 Blood-brain barrier function of P-glycoprotein Adv Drug Delivery Rev 25 287 298
49. M Vasse P Protrais J Costentin JC Schwartz 1985 Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice Naunyn Schmiedebergs Arch Pharmacol 329 108 116